Daglutril

DB05796InvestigationalSmall molecule

Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

Mechanism: SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming neutral endopeptidase and endothelin-converting enzyme inhibition. The combined inhibition of neutral endopeptidase and endothelin-converting enzyme may be useful in heart failure by reducing right and left cardiac filling pressures
Curator reviewed
Primary indication: Investigated for use/treatment in congestive heart failure and hypertension.Curator reviewed
Formula / weight: C₃₁H₃₈N₂O₆ · 534.6432 g/mol (avg)
Code names: SLV-306

Resolves to

Compound

UNIIKKV299446XCAS182821-27-8PubChem3038505

Structure

InChIKeyXMQODGUTLZXUGZ-RPBOFIJWSA-NSMILESCCOC(=O)[C@H](CCC1=CC=CC=C1)CC1(CCCC1)C(=O)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O

Targets

P08473MMEP42892ECE1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Daglutril, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account